Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin

Gillissen, B.; Richter, A.; Essmann, F.; Kemmner, W.

Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 2MB
	Other (Supplementary Material) 358kB

Item Type:	Article
Title:	Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin
Creators Name:	Gillissen, B., Richter, A., Essmann, F. and Kemmner, W.
Abstract:	BACKGROUND: Photodynamic therapy with a photosensitizer such as protoporphyrin-IX, a light sensitive metabolite of heme synthesis, is a highly selective treatment for various carcinomas. In previous studies, we found a significant down regulation of the relevant enzyme ferrochelatase in gastrointestinal carcinomas leading to an accumulation of protoporphyrin-IX within the tumor cells. Recent studies showed that a novel anti-cancer drug, Alectinib, an orally available, highly selective, potent second-generation inhibitor of anaplastic lymphoma tyrosinkinase binds to ferrochelatase. Therefore, we were interested to see whether Alectinib treatment might lead to an accumulation of protoporphyrin IX. METHODS: Tumor cells of different origin were cultured, treated with LED-light and Alectinib. Results were gained by flow cytometry, immunohistochemistry and western blotting. Apoptosis was determined by flow cytometric analysis of Annexin V-FITC stained cells. In addition, cells were counterstained with propidium iodide to distinguish early apoptotic cells and late apoptotic/necrotic cells. RESULTS: Here, we report that photodynamic treatment of tumor cell lines of different origin in combination with Alectinib increased protoporphyrin-IX specific fluorescence and concomitantly cell death. CONCLUSIONS: The usage of Alectinib could be another step for enhancing the effectiveness of photodynamic therapy. Further experiments will show whether photodynamic therapy in combination with Alectinib could be a new strategy for the treatment of e.g. peritoneal disseminated carcinomas.
Keywords:	Photodynamic Therapy, Protoporphyrin-IX, Ferrochelatase, Alectinib, Gastrointestinal Carcinomas
Source:	BMC Cancer
ISSN:	1471-2407
Publisher:	BioMed Central
Volume:	21
Number:	1
Page Range:	971
Date:	30 August 2021
Official Publication:	https://doi.org/10.1186/s12885-021-08667-x
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year